Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best‐practice guide

Abstract

Advances in biomarker‐driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker‐driven therapies and evolving indications for their use have intensified the importance of interdisciplinary communication and coordination for patients with or suspected to have lung cancer. Multidisciplinary teams are challenged with completing comprehensive and timely biomarker testing and navigating the constantly evolving evidence base for a complex and time‐sensitive disease. This guide provides context for the current state of comprehensive biomarker testing for NSCLC, reviews how biomarker testing integrates within the diagnostic continuum for patients, and illustrates best practices and common pitfalls that influence the success and timeliness of biomarker testing using a series of case scenarios.

Integrated analysis reveals critical cisplatin-resistance regulators E2F7 contributed to tumor progression and metastasis in lung adenocarcinoma

“…Lung cancer is the leading cause of cancer-related deaths globally, with more than a million fatalities each year [ 1 ]. Non-small cell lung cancer (NSCLC), which includes about 85% of all lung cancer cases, is primarily lung adenocarcinoma (LUAD), accounting for nearly half of all lung cancer cases [ 2 , 3 ].…”

New molecular insights into ferroptosis in lung adenocarcinoma progression and pharmacological compounds for targeted therapy

“…6 Advances in LUAD biomarker-driven therapy provide an opportunity to improve the treatment of patients. 7 The World Health Organization has guided the treatment of LUAD based on the expression of biomarkers since 2015, and has put more emphasis on the relationship between molecular markers and the diagnosis of LUAD in 2021. 8 With a wide range of serological, immunohistochemical, and genetic markers being evaluated, none of which are currently implemented in early diagnosis of the disease, and the epidemiological data associated with these biomarkers understudied, there is still much to explore in the field of biomarkers in LUAD.…”

“…The incidence of LUAD is still increasing among current, past and even non‐smokers and, although a variety of treatment strategies have been developed, the 5‐year survival rate is only approximately 15% despite the development of various treatment strategies 6 . Advances in LUAD biomarker‐driven therapy provide an opportunity to improve the treatment of patients 7 . The World Health Organization has guided the treatment of LUAD based on the expression of biomarkers since 2015, and has put more emphasis on the relationship between molecular markers and the diagnosis of LUAD in 2021 8 .…”

Pathological Characteristics of Fiberoptic Bronchoscopy Procedure in Ulin General Hospital, Banjarmasin

“…The procedure's effectiveness in diagnosis and treatment depends on skill, accessibility, and compliance. 7,9 This method is most commonly used to diagnose lung cancer, followed by the diagnosis of infection. It reduces the amount of pain and number of complications experienced by the patient.…”